PD
VNDA icon

Point72 (DIFC)’s Vanda Pharmaceuticals VNDA Stock Holding History

Point72 (DIFC)’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,176
Closed -$53.5K – 2095
2024
Q4 		$53.5K Buy
11,176
+8,295
+288% +$39.8K ﹤0.01% 1110
2024
Q3 		$13.5K Buy
+2,881
New +$15.4K ﹤0.01% 1238
2024
Q2 		– Sell
-16,301
Closed -$67K – 1930
2024
Q1 		$67K Buy
+16,301
New +$65.3K ﹤0.01% 1153

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Point72 (DIFC)'s VNDA Position: Q1 2025 in Review

Point72 (DIFC) sold out of Vanda Pharmaceuticals (VNDA) in Q1 2025, closing a stake of 11,176 shares — an estimated $53.5K sold.

Point72 (DIFC) first reported a position in VNDA in Q1 2024 and held it in 3 quarters. The position peaked at $67K in Q1 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q1 2025.

  • Point72 (DIFC) reported no remaining Vanda Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 11,176 Vanda Pharmaceuticals shares in Q1 2025, an estimated $53.5K.
  • Point72 (DIFC) first reported a position in Vanda Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Point72 (DIFC)'s Vanda Pharmaceuticals position peaked at $67K in Q1 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.